PMID- 25257732 OWN - NLM STAT- MEDLINE DCOM- 20150803 LR - 20221222 IS - 1878-1705 (Electronic) IS - 1567-5769 (Linking) VI - 23 IP - 2 DP - 2014 Dec TI - Immediate infusion-related adverse reactions to intravenous immunoglobulin in a prospective cohort of 1765 infusions. PG - 442-6 LID - S1567-5769(14)00367-1 [pii] LID - 10.1016/j.intimp.2014.09.015 [doi] AB - Intravenous immunoglobulin (IVIG) is increasingly recommended for many diseases apart from primary immunodeficiency diseases (PID). Although effective and safe, adverse reactions may occur. We conducted a 2-year prospective observational study in 117 patients with PID who received regular IVIG replacement therapy at a median dose of 600 mg/kg every 3 to 4 weeks to examine IVIG's adverse effects; 1765 infusions were performed (mean=15/patient) in 75 males and 42 females (aged 3 months to 77 years) in 3 groups: /= 20 years (39.3%). Fifty patients had common variable immunodeficiency (CVID), 11 had X-linked agammaglobulinemia (XLA), and 55 had other immune system disorders. The drugs administered were Octagam(R) (49.1%), Tegeline(R) (17.3%), Imunoglobulin(R) (18.6%), Flebogama(R) (12.9%), Vigam(R) (1.2%), and Kiovig(R) (0.4%). Immediate infusion-related adverse reactions occurred in the cases of 38 out 1765 infusions (2.15%, IC95% 1.53%-2.94%), which were classified as mild (81.6%), moderate (10.5%), or severe (7.9%). Time until reaction ranged from 10 to 240 min (mean = 85.7, median = 60). Reaction rates were similar across age groups. The most common reactions were malaise, headache, and abdominal pain. Reported severe events were tightness of the throat and seizure. All symptoms improved with temporary or complete IVIG interruption and symptomatic medications. Sixteen of 38 reactions to infusions occurred in the presence of an acute infection (p=0.09). Tegeline(R) represented a greater reaction risk factor than Octagam(R) (p < 0.001). These results indicate that IVIG infusion can be considered a safe procedure. Low reaction incidence and few severe immediate infusion-related adverse reactions were observed. CI - Copyright (c) 2014 Elsevier B.V. All rights reserved. FAU - Bichuetti-Silva, Danielli C AU - Bichuetti-Silva DC AD - Division of Allergy Clinical Immunology and Rheumatology, Department of Pediatrics, Federal University of Sao Paulo (UNIFESP-EPM), Rua dos Otonis 725, Sao Paulo, SP 04025-002, Brazil. Electronic address: daniellibichuete@gmail.com. FAU - Furlan, Fernanda P AU - Furlan FP AD - Division of Allergy Clinical Immunology and Rheumatology, Department of Pediatrics, Federal University of Sao Paulo (UNIFESP-EPM), Rua dos Otonis 725, Sao Paulo, SP 04025-002, Brazil. Electronic address: nandafurlan@hotmail.com. FAU - Nobre, Fernanda A AU - Nobre FA AD - Division of Allergy Clinical Immunology and Rheumatology, Department of Pediatrics, Federal University of Sao Paulo (UNIFESP-EPM), Rua dos Otonis 725, Sao Paulo, SP 04025-002, Brazil. Electronic address: aimeenobre@yahoo.com.br. FAU - Pereira, Camila T M AU - Pereira CT AD - Division of Allergy Clinical Immunology and Rheumatology, Department of Pediatrics, Federal University of Sao Paulo (UNIFESP-EPM), Rua dos Otonis 725, Sao Paulo, SP 04025-002, Brazil. Electronic address: milatmp@hotmail.com. FAU - Goncalves, Tessa R T AU - Goncalves TR AD - Division of Allergy Clinical Immunology and Rheumatology, Department of Pediatrics, Federal University of Sao Paulo (UNIFESP-EPM), Rua dos Otonis 725, Sao Paulo, SP 04025-002, Brazil. Electronic address: tessarachel@gmail.com. FAU - Gouveia-Pereira, Mariana AU - Gouveia-Pereira M AD - Division of Allergy Clinical Immunology and Rheumatology, Department of Pediatrics, Federal University of Sao Paulo (UNIFESP-EPM), Rua dos Otonis 725, Sao Paulo, SP 04025-002, Brazil. Electronic address: ma_rianinha@yahoo.com.br. FAU - Rota, Rafael AU - Rota R AD - Division of Allergy Clinical Immunology and Rheumatology, Department of Pediatrics, Federal University of Sao Paulo (UNIFESP-EPM), Rua dos Otonis 725, Sao Paulo, SP 04025-002, Brazil. Electronic address: rota72@hotmail.com. FAU - Tavares, Lusinete AU - Tavares L AD - Division of Allergy Clinical Immunology and Rheumatology, Department of Pediatrics, Federal University of Sao Paulo (UNIFESP-EPM), Rua dos Otonis 725, Sao Paulo, SP 04025-002, Brazil. Electronic address: lusinete_tavares@gmail.com. FAU - Mazzucchelli, Juliana T L AU - Mazzucchelli JT AD - Division of Allergy Clinical Immunology and Rheumatology, Department of Pediatrics, Federal University of Sao Paulo (UNIFESP-EPM), Rua dos Otonis 725, Sao Paulo, SP 04025-002, Brazil. Electronic address: juliana.mazzuccheli@gmail.com. FAU - Costa-Carvalho, Beatriz T AU - Costa-Carvalho BT AD - Division of Allergy Clinical Immunology and Rheumatology, Department of Pediatrics, Federal University of Sao Paulo (UNIFESP-EPM), Rua dos Otonis 725, Sao Paulo, SP 04025-002, Brazil. Electronic address: beacarvalho@terra.com.br. LA - eng PT - Journal Article DEP - 20140922 PL - Netherlands TA - Int Immunopharmacol JT - International immunopharmacology JID - 100965259 RN - 0 (Immunoglobulins, Intravenous) SB - IM MH - Adolescent MH - Adult MH - Aged MH - Child MH - Child, Preschool MH - Cohort Studies MH - Female MH - Humans MH - Immunoglobulins, Intravenous/*adverse effects/*therapeutic use MH - Immunologic Deficiency Syndromes/*drug therapy MH - Infant MH - Male MH - Middle Aged MH - Odds Ratio MH - Risk Factors MH - Young Adult OTO - NOTNLM OT - Adverse reactions OT - Antibody OT - Infusion-related OT - Intravenous immunoglobulin OT - Primary immunodeficiency EDAT- 2014/09/27 06:00 MHDA- 2015/08/04 06:00 CRDT- 2014/09/27 06:00 PHST- 2014/06/18 00:00 [received] PHST- 2014/09/01 00:00 [revised] PHST- 2014/09/10 00:00 [accepted] PHST- 2014/09/27 06:00 [entrez] PHST- 2014/09/27 06:00 [pubmed] PHST- 2015/08/04 06:00 [medline] AID - S1567-5769(14)00367-1 [pii] AID - 10.1016/j.intimp.2014.09.015 [doi] PST - ppublish SO - Int Immunopharmacol. 2014 Dec;23(2):442-6. doi: 10.1016/j.intimp.2014.09.015. Epub 2014 Sep 22.